* Q4 sales of SEK 43m (-11% y-o-y), in line with pre-announcement * EBIT SEK -4m (vs.
Suominen reports Q4 results on Jan 29. FY’26 should see better earnings, yet growth may still be har...
* Q4e: US stable with Germany improving sequentially * U.
* Mild winter in Q4, but sequentially easing comps: organic growth -1% * Cost savings took effect in...
Redeye leaves a comment following OncoZenge’s announcement regarding the delayed payment of tranche ...
Redeye provides commentary on NextCell following the announcement of a SEK15m directed issue and a s...
YIT reports its Q4 results on February 6th. Aided by apartment unit completions, we expect to see th...
Redeye initiates coverage of Coffee Stain Group, a Swedish game development company recognised for i...
* We cut 2025e sales by SEK 21m, reflecting no machine deliveries * Rights issue of ~SEK 26.
Redeye comments on Avensia’s December sales figures.
Redeye is positive on Senzime’s new contract with an Ivy League US hospital.
Prostatypes USA-studie har nyligen presenterats i en vetenskaplig tidskrift.
Timing of project revenue recognition is set to boost Q4 figures.
Cicor is an electronics manufacturing services (EMS) company with ~60 years of history, and we view ...
Seafire saw increasing stability during 2025, driven by internal efficiency measures and recovering ...
Redeye gives an initial take on the news that IRLAB has entered into a collaboration with Biomia reg...
Redeye initiates coverage of Guldbrev, the market-leading digital gold buyer in Sweden.
* Q4'25 numbers due on 10 February at 07:45 CET * Expect new targets on the reporting day, more info...
Redeye provides a quick comment on Cheffelo’s reverse profit warning for Q4 2025, released earlier t...
This morning SyntheticMR announced preliminary Q4 figures amid the ongoing rights issue.
